Shares of Novo Nordisk (NYSE: NVO) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Sharon was on hand to promote the event alongside the band's originals guitarist Tony Iommi, after admitting she is ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Ram Kapoor has left the internet amazed with his impressive body transformation. In a viral video, the actor opened up, ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

In emotional scenes, the former OnlyFans model, 27, couldn't keep it together as she candidly told her co-stars that her 2022 ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its mid-December bear gap, after which it hit a Jan. 17, 52-week low of $78.17 amid ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...